Ambrx Biopharma Inc AMAM announced new preclinical data from studies ARX517 and ARX305 at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) – Cellectis (the “Company”) CLLSa clinical-stage biotechnology company using its breakthrough gene-editing platform to develop life-saving cell and
SAN DIEGO, March 7, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. CDTXa biotechnology company developing long-acting therapeutics designed to help improve the standard of care
Celyades Oncology CYAD offers an update on its Celyad 2.0 business strategy, which has been adopted and implemented in recent months. The company has
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 demonstrated combinatorial utility with the BCL-2 inhibitor
of MorphoSys AG MOR subsidiary Constellation Pharmaceuticals Inc Has entered into a global license agreement Novartis AG NVS to discover, develop and commercialize its preclinical
BMF-500, an investigational third-generation covalent FLT3 inhibitor, has shown preclinically to be possibly the most potent and selective inhibitor of FLT3 studied to date: Greater
From allergies and insect bites to sunburn and irritation, human skin can succumb to a variety of conditions including acne, psoriasis, blisters, hives, actinic keratosis,
fosgo-AM, the active metabolite of fosgonimetone (ATH-1017), shows neuroprotective effects in primary neuronal culturesNovel orally available small molecule positive modulators of HGF/MET reverse memory deficits
When inventors need an NDA, what it actually protects, and the routine confidentiality habits that keep patent options open before filing.
Recovery after a serious car accident often takes weeks to months, while severe injuries may require a year or longer. The first 72 hours usually
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind